See more : Benitec Biopharma Inc. (BNTC) Income Statement Analysis – Financial Results
Complete financial analysis of Candel Therapeutics, Inc. (CADL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Candel Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nippon Information Development Co., Ltd. (2349.T) Income Statement Analysis – Financial Results
- KeyCorp (KEY-PJ) Income Statement Analysis – Financial Results
- NEOJAPAN Inc. (NEOJF) Income Statement Analysis – Financial Results
- Incheon City Gas Co., Ltd. (034590.KS) Income Statement Analysis – Financial Results
- REN – Redes Energéticas Nacionais, SGPS, S.A. (RENE.LS) Income Statement Analysis – Financial Results
Candel Therapeutics, Inc. (CADL)
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 125.00K | 125.00K | 125.00K | 125.00K |
| Cost of Revenue | 23.98M | 987.00K | 232.00K | 0.00 | 6.61M |
| Gross Profit | -23.98M | -862.00K | -107.00K | 125.00K | -6.48M |
| Gross Profit Ratio | 0.00% | -689.60% | -85.60% | 100.00% | -5,185.60% |
| Research & Development | 24.51M | 20.79M | 15.18M | 8.75M | 6.61M |
| General & Administrative | 13.72M | 14.06M | 10.67M | 5.18M | 2.56M |
| Selling & Marketing | 687.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.41M | 14.06M | 10.67M | 5.18M | 2.56M |
| Other Expenses | -24.51M | -48.00K | -1.08M | -624.00K | -571.00K |
| Operating Expenses | 14.41M | 34.80M | 24.78M | 13.31M | 8.59M |
| Cost & Expenses | 38.39M | 34.80M | 24.78M | 13.31M | 8.59M |
| Interest Income | 0.00 | 490.00K | 53.00K | 111.00K | 1.07M |
| Interest Expense | 514.00K | 490.00K | 53.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 960.00K | 987.00K | 232.00K | 91.00K | 43.00K |
| EBITDA | -37.43M | -17.32M | -25.49M | -13.72M | -8.20M |
| EBITDA Ratio | 0.00% | -40,835.20% | -19,534.40% | -6,792.00% | -6,063.20% |
| Operating Income | -38.39M | -34.72M | -25.73M | -13.81M | -9.04M |
| Operating Income Ratio | 0.00% | -27,777.60% | -20,580.80% | -11,048.00% | -7,229.60% |
| Total Other Income/Expenses | 452.00K | 15.93M | -10.40M | -3.87M | 797.00K |
| Income Before Tax | -37.94M | -18.79M | -36.12M | -17.68M | -8.24M |
| Income Before Tax Ratio | 0.00% | -15,035.20% | -28,899.20% | -14,144.00% | -6,592.00% |
| Income Tax Expense | 0.00 | -15.93M | 53.00K | 4.49M | -226.00K |
| Net Income | -37.94M | -2.87M | -36.18M | -22.17M | -8.01M |
| Net Income Ratio | 0.00% | -2,292.80% | -28,941.60% | -17,739.20% | -6,411.20% |
| EPS | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| EPS Diluted | -1.31 | -0.10 | -1.26 | -0.76 | -0.27 |
| Weighted Avg Shares Out | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
| Weighted Avg Shares Out (Dil) | 28.94M | 28.82M | 28.69M | 29.15M | 29.15M |
Candel Therapeutics is pushing for a paradigm shift in cancer treatment
Cancer treatment has long been dominated by traditional approaches such as surgery, radiation, and chemotherapy. But in recent years, a wave of innovation has emerged, driven by the promise of immunotherapies that harness the body's own immune system to fight...
Candel Therapeutics CEO: Putting patients first is the key to reframing cancer treatment
In the biopharmaceutical world, where innovation and breakthroughs often dominate headlines, a fundamental question is frequently overlooked: are we truly listening to patients? For Paul Peter Tak CEO of Candel Therapeutics Inc (NASDAQ:CADL), the answer has shaped a career rooted...
Candel Therapeutics CEO anticipates 'paradigm shift' in prostate cancer treatment as Q3 work wraps up
Candel Therapeutics Inc (NASDAQ:CADL) CEO Paul Peter Tak expressed optimism for a "paradigm shift" in prostate cancer treatment as the biopharmaceutical company moves closer to phase 2b and phase 3 trial data releases for its lead therapy, CAN-2409. Tak stated...
Candel Therapeutics' CAN-3110 offers new hope for melanoma treatment – ICYMI
Candel Therapeutics Inc (NASDAQ:CADL) recently presented insights into its oncolytic virus therapy, CAN-3110, at the Society for Immunotherapy of Cancer (SITC) conference. The company's Chief Scientific Officer, Dr.
Candel Therapeutics eyes new indication for CAN-3110 in melanoma following positive preclinical results
Candel Therapeutics Inc (NASDAQ:CADL) announced that preclinical data from its CAN-3110 program indicate promising antitumor activity in melanoma, suggesting a potential expansion beyond the candidate's original focus on recurrent high-grade glioma. The findings, to be presented at the Society for...
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
NEEDHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced preclinical results and therapeutic potential of...
Candel Therapeutics: A Low-Price Oncolytic Virus Plays Further Along Than You Think
Candel Therapeutics is working on intratumoral oncolytic virus therapy. A pair of mid to late-stage trials in prostate cancer are expected to read out in Q4. Positive findings could be the position of strength the company needs to raise funds,...
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present a poster...
3 Biotech Names With Potential Catalysts By Year End
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should continue to advance. Today, we look in...
Candel Therapeutics to Join Russell 3000® Index
NEEDHAM, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company is set...
Source: https://incomestatements.info
Category: Stock Reports